STOCK TITAN

AbCellera Biologics Inc - ABCL STOCK NEWS

Welcome to our dedicated news page for AbCellera Biologics (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on AbCellera Biologics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AbCellera Biologics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AbCellera Biologics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
conferences earnings
-
Rhea-AI Summary
DAMONA Pharmaceuticals appoints John Reilly as CEO and member of the Board of Directors, bringing two decades of leadership experience in biotechnology companies. Reilly's expertise in corporate strategy, business development, and R&D will be crucial in advancing DAMONA's lead asset towards clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.38%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.07%
Tags
partnership
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
none
AbCellera Biologics Inc

Nasdaq:ABCL

ABCL Rankings

ABCL Stock Data

1.19B
191.76M
28.09%
43.66%
8.06%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
CA
Vancouver

About ABCL

abcellera is a canadian biotechnology company focused on accelerating the discovery of monoclonal antibody (mabs) therapeutics. antibodies are molecules that are naturally produced by the immune system of humans or animals to fight off infection and disease. the unique property of antibodies is that they can specifically recognize and target diseased cells or pathogens, making them precise and highly effective drugs with low side effects for the treatment of cancer, autoimmune disorders and infections. the immune system is capable of making billions to trillions of unique antibodies, each produced by a single immune cell. of these, only a select few are suitable for therapeutic applications. finding these rare antibodies presents a major roadblock in the development of new therapeutics. abcellera addresses this bottleneck by using microfluidic technology for the rapid and high-throughput analysis of antibodies directly from single cells. abcellera is a spinoff from dr. carl hansen’